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Lung cancer belongs to a group of tumors with bad prognosis 
resulting in limited therapeutic chances. It is the most common cause of 
cancer deaths and cancer-related deaths worldwide. Only 25-40% of lung 
cancers are considered resectable when a diagnosis is made and just 20% 
of patients have a confined disease at the time of surgery. That makes 
problem of early diagnosis of lung cancer one of the biggest challenges in 
clinical oncology. Our goal was to determine whether molecular genetic 
assays  could  augment  conventional  clinical  and  laboratory  diagnostic 
procedures.  
Bronchoalveolar  aspirate  of  patients  with  different  histological 
types  and  stages  of  NSCLC  were  analyzed  for  presence  of  K-ras 70  GENETIKA, Vol. 41, No. 1,69 -80, 2009. 
oncogene mutations (codons 12 and 13) and compared with cytological 
findings in the same samples.  
Mutations  in  codons  12  and  13  of  K-  and  H-ras  genes  in 
bronchoalveolar  aspirate  of  53  patients  (pts)  were  examined  by 
polymerase chain reaction and SSCP analysis.   
Mutations  in  K-ras  gene  were  identified  in  18/53  (34%) 
specimens  of  bronchoalveolar  aspirate,  out  of  which  3/18  were 
adenocarcinomas,  11/18  squamous  cell  carcinoma,  two  were  with 
anaplastic and two patients with chronical lung disease. The same samples 
were  examined  for  presence  of  malignant  cells  by  conventional 
cytological analysis. Normal cytological results were found in 6 samples 
of  patients  with  malignant  tumors  out  of  which  K-ras  mutations  were 
detected in 4 samples.  
A  presence  of  mutated  K-ras  gene  may  prove  useful  as  an 
adjunct to cytological analysis and also could serve as additional criteria 
for early diagnosis in patients with bronchogenic carcinoma.   
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INTRODUCTION 
Lung  cancer  is  a  tumor  with  limited  therapeutic  chances  and  bad 
prognosis.  Only  25-40%  of  lung  cancers  can  be  surgically  removed  when  a 
diagnosis is made and just 20% of people have a confined disease when they are 
surgically treated, so far, the most effective way of treating of the cancer (ANĐELIĆ 
et al. 2001). 
Despite  many  efforts,  there  is  no  significant  progress  in  treating  lung 
cancer.  Because  of  the  increasing  number  of  lung  cancer  patients,  medical 
approach  to  lung cancer  must  be  directed  to  prevention  and  early  diagnosis  of 
disease. During recent decades the development of molecular oncology strongly 
have influenced the understanding of molecular events including the initiation and 
progression of lung cancer, giving the hope that early detection of lung cancer cells 
will be possible in the near future. 
Among the most common genetic changes in lung cancer are mutations of 
ras genes. Ras gene family contains three well characterized functional genes K-, 
H- and N-ras . Their products are similar proteins (molecular mass 21KD) having a 
crucial  role  in  transduction  of  external  signals  which  regulate  cell  growth  and 
differentiation. Through many post translational modifications protein is located at 
internal side of cellular membrane. Thus both "wild-type" (WT) and mutated ras 
gene  interact  with  proteins  included  in  signal  transduction.  Point  mutations  in 
codons  12,  13  and  61  of  ras  genes  activate  them  as  oncogenes  causing 
conformational  changes  that  lead  to  permanent  activation  that  stimulate 
autonomous and infinite cell growth. (BISHOP, 1991) 
Changes in K-ras gene in codon 12 are the most common (80-90%) G-T 
transversion  and  predominantly  present  in  25-40%  atypical  adenomatous V. ILIĆ et al : DETECTION OF K-RAS GENE MUTATION                                                             71 
hyperplasia’s. (ZHANG, 2008.)  Many molecular studies of the presence of K-ras 
mutations in lung cancer are based on analysis of body liquids, usually of sputum, 
bronchoalveolar  fluid  –lavage  (BAL),  aspirate  or  serum  and  plasma  samples. 
Numerous PCR techniques, besides conventional PCR (like PCR-PIREMA, PCR-
RFLP  etc.)  enable  detection  of  mutated  K-  ras  allele  in  a  sample  of  BAL  in 
patients (56%) with diagnosis of primary adenocarcinoma as well as in the patients 
(31%) with large cell lung carcinoma. (SOMERS, 1998). Significant percent of K-
ras mutation was observed in lung tissue without neoplastic phenotype in 60% 
patients  with  NSCLC  as  well  as  in  lung  tissue  of  12%  patients  with  benign 
diagnosis. Furthermore, comparison of the results  for the presence of mutations 
obtained by PCR method with negative cytological results in sputum, showed that 
tumor specific mutations were present in 7/8 samples  (YAKUBOVSKAYA et al., 
1995). 
It  is  obvious  that  results  of  standard  diagnostic  procedures,  such  as 
cytology,  radiography  and  bronchoscopy,  are  not  quite  satisfactory  for  early 
diagnosis of the disease and consecutively for better therapy results. Anamnestic 
information like history of smoking, professional exposure to carcinogens indicates 
the need for disease prevention and different approaches to a particular patient. 
Improving  sensitivity  of  molecular testing  will  enable use  of  less  invasive and 
more sensitive and specific diagnostic procedures, thus giving advantage in early 
diagnosis of disease. 
This  study  was  aimed to  detect  point mutations in K-ras  oncogene  in 
bronchial aspirate of patients with suspected lung cancer, and further to compare 
obtained results with cytological and patohistological results in the same samples.   
 
 
MATERIAL AND METHODS 
 
Patients 
Samples  for  analysis  were  obtained  from  patients  aspirates  during 
bronchoscopia at the functional diagnostics unit, Clinic for Pulmology (MMA). 
During  the  preliminary  analysis  we  found  out  that  bronchial  aspirate  samples 
appears to be better than BAL and pleural excretion, concerning that a particular 
material is obtained directly from the lesions without any additional procedures. 
After  pathohistological  examination  from  53  collected  samples,  8  were 
inflammatory changes, 3 patients had chronical obstructive pulmonal disease, 23 
patients with planocelular carcinoma, 11 with adenocarcinoma, 3 adenosquamous 
and  3  with  anaplastic  lung carcinoma (Table  1.) The majority  of  patients  with 
confirmed lung cancer (examined group consisted of 44 man and 9 women patients 
aging from 41 to 76 year), were classified as stage IIIb and IV, and all of them 
received presurgical irradiation. 
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Table 1. Diagnosis and tumor classification of examined group of patients 
 
HOCD-chronic opstructive lung disease;  
Ca. plano.-Planocelular lung cancer; 
Ca.adskv.-Adenosquamouslung cancer; 
Ca. anap.-Anaplastic lung cancer; 
Ca. aden.- Adenocarcinoma; 
Pleuritis – inflamation of pleura; 
SCLC – small cell lung cancer; 
NSCLC – non-small cell lung cancer 
 
 
Methods 
 
DNA isolation 
DNA  from  bronchial  aspirate  was  isolated  by  phenol-chlorophorm 
extraction. After precipitation of DNA at -20˚C, rinsing with absolute ethanol and 
drying, collected DNA was resuspended in the 100µl of redestilated water.   
‘ 
Detection of K-ras mutation 
PCR was  performed  in 50µl  of reaction  mixture which finally  include 
400-600 ng templates DNA, 1XPCR buffer with 10mM KCl and 1, 5 mM MgCl2, 
0, 2 mM d NTP mix, 25 pmol of each primer and 1 U of Taq polymerase. The 50µl 
mixture was incubated in Eppendorf thermocycler for 35 cycles of denaturation, 
annealing and extension at 95ºC, 51ºC and 72ºC, respectively. First reaction was 
initiated with one 10-minute incubation cycle at 95ºC and ended with a 10 minute 
elongation at 72ºC. Primer sequences for the I exon of K-ras gene is:  
5'- ATG ACT GAA TAT AAA CTT GT-3' 
5'- CTC TAT TGT TGG ATC ATA TT -3' 
PCR  product  was  visualized  by  agarose  and  K-ras  mutations  were 
detected  by  acrilamide  Single  Strand  Conformation  Polymorphism  (SSCP) 
electrophoresis. 
 
Diagnosis  Number 
HOCD  3 
Pleuritis  8 
SCLC  2 
*  I  II  IIIa  IIIb  IV   
Ca.plano  1  1  6  9  6   
Ca.adskv.        3     
Ca. anap.      2  1     
 
 
NSCLC 
Ca. aden.      1  8  2   
 
 
40 
Total    1  1  9  21  8    53 V. ILIĆ et al : DETECTION OF K-RAS GENE MUTATION                                                             73 
Statistics 
Statistical analysis of frequency distributions was evaluated by Student’s t 
test,  χ2 and/or Fisher′s exact test. 
 
 
RESULTS  
 
We analyzed bronchial aspirates of patients from Clinic for Pulmology in 
order to detect presence of mutations into the first exon (codons 12 and 13) of K-
ras gene, the most often symptoms were cough, pain, hoarseness, breath rhythm 
disturbance  and  a  hart  weakness.  Among  53  patients,  through  further  clinical 
examinations, 11 had inflammatory changes while 42 were positive for malignant 
lung neoplasia and further were classified as advanced stage of disease (III and IV 
stage). 
 
K-ras mutations were present in 2/11 patients with inflammatory changes 
(18%) and in 16/42 with malignant neoplasm’s (38%) (Figure 1.) There was no 
statistically significant difference between patients with inflammatory changes and 
malignant neoplasm′s in the frequency of K-ras mutations. 
 
 
Figure 1. Distribution of K-ras mutation in a group of patients  
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K-ras  mutations  were  distributed  within  different  histological  types  as 
following: in squamous cell carcinoma (11/23), adenocarcinoma (3/12), as well as 
in  two  patients  with  diagnosis  of  anaplastic  carcinoma  and  two  with  chronic 
obstructive lung disease (Figure 2.) 
  
 
Figure 2. Distribution of K-ras mutation in examined group of patients according to 
histological classification of NSCLC 
 
9/11patients  with  metastatic  disease  (metastasis  in  pleura,  chilus  and 
supraclavicular region) had mutated K-ras gene (Figure 3.) 
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Comparison  of  personal  anamnestic  data  with  the  incidence  of  K-ras 
mutation in the bronchial aspirate samples of patients showed that  a considerable 
number of them was in the group of active or former smokers (30.8 ± 12.6 year) 
(Figure 4.) 
 
 
 
Figure 4.Median value with standard deviation of smoking  duration and daily cigarete 
consuming in examined group 
 
  Concerning total number of patients with K-ras mutations (n=18), 17/18 
were active smokers (Figure 5.) 
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Figure 5. Distribution of active and former smokers in a group of patients with 
detected K-ras mutation 
 76  GENETIKA, Vol. 41, No. 1,69 -80, 2009. 
  PCR and cytological analysis were performed from the same samples of 
bronchial  aspirate.  In  the  6  samples  with  confirmed  diagnosis  of  cancer  
(patohistological examination) cytological findings were normal. Furthermore, the 
presenc of K-ras mutations in the 4 of these samples was detected. ( Figure 6.) 
 
 
 
DISCUSSION 
Lung cancer may develop without any symptoms. It appears in the form 
of little knots at the lung edges, and patohistological and cytological analyses are 
crucial for a final diagnosis. When lesions are not available for bronchobiopsy or 
when biopted sample is not easy to be analyzed hystopathologically, a diagnosis 
relies on cytological analysis of aspirate and bronchoalveolar lavage. This analysis 
are  not  always  reliable  enough  especially  when  lesions  are  smaller  than  2  cm 
(OSHITA et al., 1999). 
The purpose of our study was to analyze the presence of activating point 
mutations in the K-ras gene in the bronchial aspirate of patients which came to 
pulmologist for the first time. Aspirate was taken during routine bronchoscopic 
diagnostic procedure. Using PCR-SSCP method, mutations in exon I (codons 12 
and 13) of K-ras gene were found in 18 out of 53 tested patients (34%), what is in 
accordance with incidence of mutations, which is set by use of the same technique 
in  previous  studies,  and  it  varied  from  25  to  48%  (MINAMOTO  et  al.,  2000). 
Although, mutations in Ras gene family are usually found in adenocarcinoma we 
have detected in 18% of tested patients what is less than in other studies (30-56%), 
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Figure 6. Distribution of the K-ras presence and  citological findings 
conformity  in bronchial aspirate samples 
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while we found more mutations in K-ras gene in advanced stage of planocellular 
lung cancer (48%) (SOMERS et al., 1998).  
In the study of Graziano and Gamble (GRAZIANO et al., 1999), one out of 
61 patients with squamous cell carcinoma had K-ras mutation. Other studies found 
no K-ras mutations in the 43 samples of squamous cell carcinomas (RODENHUIS 
and SLEBOS, 1992).  Also, one mutation was found in 37 squamous cell carcinoma 
samples (3%) (KEOHAVONG et al., 1996). Contrary to these results, some non-US 
studies  reported  significant  percentage  of  squamous  cell  carcinoma  with  K-ras 
mutation (up to 59% ) (ROSELL, 1996; TOMIDA, 2004). 
The contradictory findings of different groups indicate the possibility that 
detection  of  mutations  also  depends  on  the  sensitivity  and  specificity  of  used 
method, as well as on the quality of analyzed samples. Previous detection of K-ras 
mutation in human cancers is changed by the use of sensitive techniques such as 
PCR-pirema,  Point-exact  method  (which  using  coupled  capture  technique  and 
exonucleases, enables detection of one mutated cells out of 15000 normal cells), 
PCR-RFLP method, Southern blot, etc. 
Since  genetic  basis  of  malignant  changes  is  relatively  well  examined 
sufficient importance is attached to an early detection (molecular-genetic level) of 
cancer cells.  It is a widespread opinion that ras mutations occurs relatively early in 
lung cancer (WRIGHT and GRUIDL, 2000). In human cancers K-ras mutations are 
detected in adenomas of colon, pancreatic hyperplasia where they were defined as 
an early event of cancer development (MINAMOTO et al., 2000). Ras mutations are 
detected in the case of former smokers who have not smoked for more than 15 
years before the occurrence of malignancy, as well as in a sputum samples taken a 
year before clinical diagnosis of lung cancer (KIRSI and WILIAM, 2001).  
  Numerous  studies  (CLAYTON  et  al.,  2000)  confirm  the  possibility  of 
difference in PCR and cytological results in detection of malignant cells in BAL. 
Percentage of detection of K-ras mutation in samples which are not cytological 
diagnosed  as  malignant,  sometimes  is  more  than  20%  (KEOHAVONG  and  DE 
MICHELLE,  2000).  Comparing  cytological  findings  with  detection  of  K-ras 
mutations in the samples of patients with lung cancer we have detected that out of 
43  lungs  cancer  patients  6  were  with  normal  cytology,  and  in  the  4  of  these 
samples K-ras mutation was found. According to accessible information (SOMERS 
et  al.,  1998)  time  between  K-ras  point  mutation  detection  in  sputum,  aspirate 
cytology and clinical diagnosis of lung cancer varied from 1 month to almost 4 
years. Molecular screening of genes involved in lung carcinogenesis thus would be 
valuable addition to standard cytological analysis as we have found in our study. 
  Research  results  (HECHT,  1999)  emphasize  fact  that  carcinogens  from 
cigarettes and smoke induce ras oncogene mutations, and in connection (HEATHER 
et  al.,  1999)  also  showed  the  increasing  incidence  of  K-ras  mutations  in  lung 
cancer in women. In our study all female patients were smokers for a long time and 
K-ras mutation was detected in two patients, one with HOBP and the other with 
lung adenocarcinoma. According to recent information one of the mechanisms of 
selecting  K-ras  mutated  clone  is  considered  to  be  hormonally  mediated  by 78  GENETIKA, Vol. 41, No. 1,69 -80, 2009. 
estrogens (PATEL and PETER, 2004). Actually it is known that precursor cells of 
adenocarcinoma  increase  expression  of  estrogen  receptors  and  thus  cause  the 
promotion of growth factors caused by this hormone unlike the other cellular lines 
of non-small cell lung cancer.  
  Patients  with  III  stadium  of  tumor  are  usually  treated  with  additional 
radiotherapy. The  decision about selection of patients which will  be treated by 
radiotherapy is made, first of all, according to histological and clinical parameters 
(CHOI et al., 2001). It is noticed that patients with tumors of similar histological 
characteristics react differently to radiotherapy (ADJEI, 2001). Having in mind that 
K-ras mutation increase resistance to radiotherapy, detection of K-ras mutation 
may be an additional information which could be included in prediction of tumor 
sensitivity  to  radiotherapy  (BERNHARD  et  al.,  2000)  enabling  in  that  way 
appropriate treatment and better prognosis. Determination of K-ras gene status in 
advanced-stage tumor΄s can be of a great importance in prognostic and guiding 
treatment decisions. (ELAINE et al., 2009). Also, presence of K-ras mutations in the 
tumor  tissue  of  patients  with  colon  cancer  is  a  strong  predictive  factor  to  the 
therapy with monoclonal antibody against epidermal growth factor receptor (TOL et 
al., 2009). 
 
CONCLUSION 
 
Results obtained in this study indicate that usage of molecular markers 
can be valuable additional diagnostic procedure to standard cytological analyses 
for early detection of malignant cells in patients with lung cancer. Furthermore, 
these results can be used for improvement of patent treatment. 
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Izvod 
   
Karcinom pluća je maligni tumor sa lošom prognozom koji pruža male 
terapijske mogucnosti. Svega 25-40% karcinoma pluća je operabilno u vreme kada 
se postavi dijagnoza, a samo 20% njih ima ograničenu bolest u vreme kada se 
podvrgavaju  hirurškom  lecenju  -  do  sada  najefikasnijem  vidu  lečenja  ovog 
karcinoma.  Pri  tome  je  petogodišnje  preživljavanje  samo  13%  a  veliki  broj 
pacijenata  umire  već  u  toku  dve  godine  po  postavljanju  dijagnoze.  Kako  je 
efikasnost  lečenja  ovog  karcinoma  jos  uvek  niska,  neophodni  su  novi  pristupi 
bolesti koji se tiču pre svega rane dijagnostike primenom molekularnih markera. 
Pojava ras mutacija u ranim stadijumima karcinoma pluća predstavljala bi koristan 
marker koji bi omogućio raniji početak lečenja i time poboljšao njegov ishod. U 
radu su analizirane mogućnosti detekcije tačkastih mutacija u K-ras onkogenu u 
aspiratu  bronha  dobijenim  tokom  rutinske  bronhoskopske  dijagnostike  u  cilju 
blagovremenog otkrivanja bolesti kao i korelacija prisustva mutacija sa dobijenim 
citološkim i patohistološkim rezultatima. Mutacije u K-ras genu su nađene u 18/53 
(34%)  uzorka  bronhijalnog  aspirata  od  kojih  je  3/18  histološkog  tipa 
adenokarcinoma,  11/18        planocelularnog,  kod  dva  pacijenta  sa  anaplastičnim 
karcinomom  i  dva  sa  dijagnozom  hronične  opstruktivne  bolesti  pluća. 
Nepodudarnost rezultata citološkog pregleda i histopatološkog nalaza je nađena u 6 
uzoraka, kod kojih je patohistoloskom analizom nadjena maligna bolest a citoloski 
nalaz je bio normalan. Kod 4 od 6 uzoraka nadjene su K-ras mutacije. Sledstveno 
tome, izmena u K-ras genu detektovana in vitro testom u kliničkom uzorku može 
biti dodatni dijagnosticki i prediktivni marker karcinoma pluca.   
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